Amendments to the Claims

- 1. (currently amended) A <u>dose form of sumatriptan comprising composition for delivery of sumatriptan consisting of</u> a condensation aerosol
- a) formed by volatilizing heating a thin layer of sumatriptan containing sumatriptan, on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of sumatriptan and condensing the heated vapor of sumatriptan to form a condensation aerosol particles,
- b) wherein said condensation aerosol particles are characterized by less than 5% 10% sumatriptan degradation products by weight, and
- e) the condensation aerosol has an MMAD of less than 3 microns, wherein the dose form comprises less than 20 mg of sumatriptan.

2.-3. (cancelled)

- 4. (currently amended) A <u>dose form of frovatriptan comprising composition for delivery of frovatriptan consisting of a condensation aerosol</u>
- a) formed by volatilizing heating a thin layer of frovatriptan containing frovatriptan, on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of frovatriptan and condensing the heated vapor of frovatriptan to form a condensation aerosol particles.
- b) wherein said condensation aerosol particles are characterized by less than 5% 10% frovatriptan degradation products by weight, and
- e) the condensation aerosol has an MMAD of less than 3 microns 5 microns, wherein the dose form comprises less than 2 mg of frovatriptan.

5.-6. (cancelled)

- 7. (currently amended) A <u>dose form of naratriptan comprising</u> composition for delivery of naratriptan consisting of a condensation aerosol
- a) formed by volatilizing heating a thin layer of naratriptan containing naratriptan, on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of naratriptan and condensing the heated vapor of naratriptan to form a condensation aerosol particles,
 - b) wherein said condensation acrosol particles are characterized by less than 5% 10% naratriptan

degradation products by weight, and

e) the condensation acrosol has an MMAD of less than 3-microns 5 microns, wherein the dose form comprises less than 0.8 mg of naratriptan.

8.-9. (cancelled)

- 10. (currently amended) A method of producing <u>a dose form of sumatriptan comprising a</u> condensation aerosol, the method in an aerosol form comprising:
- a. heating a thin layer of sumatriptan containing sumatriptan, on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the sumatriptan to form a heated to produce a vapor of the sumatriptan, and
- b. during said heating, passing air providing an air flow through the heated vapor to produce to form a condensation aerosol particles of the sumatriptan comprising characterized by less than 5% 10% sumatriptan degradation products by weight, and an aerosol having an MMAD of less than 3 microns 5 microns, wherein the dose form comprises less than 20 mg of sumatriptan.

11.-12. (cancelled)

- 13. (currently amended) A method of producing <u>a dose form of frovatriptan comprising a</u> condensation acrosol, the method in an acrosol form comprising:
- a. heating a thin layer of frovatriptan containing frovatriptan, on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the frovatriptan to form a heated to produce a vapor of the frovatriptan, and
- b. during said heating, passing air providing an air flow through the heated vapor to produce to form a condensation aerosol particles of the frovatriptan comprising characterized by less than 5% 10% frovatriptan degradation products by weight, and an aerosol having an MMAD of less than 3 microns 5 microns, wherein the dose form comprises less than 2 mg of frovatriptan.

14.-15. (cancelled)

- 16. (currently amended) A method of producing <u>a dose form of naratriptan comprising a condensation aerosol, the method in an aerosol form comprising:</u>
- a. heating a thin layer of naratriptan containing naratriptan on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the naratriptan to form a heated to

produce a vapor of the naratriptan, and

b. during said heating, passing air providing an air flow through the heated vapor to produce to form a condensation aerosol particles of the naratriptan comprising characterized by less than 5% 10% naratriptan degradation products by weight, and an aerosol having an MMAD of less than 3 microns 5 microns, wherein the dose form comprises less than 0.8 mg of naratriptan.

17.-18. (cancelled)